Equillium, Inc.
February 06, 2025 - by Joey Ramson
$EQ is leading the Prism MarketView Biotech index. Equillium announced positive data from its Phase 2 Study evaluating Itolizumab in Patients with moderate to severe Ulcerative Colitis
$EQ is leading the Prism MarketView Biotech index. Equillium announced positive data from its Phase 2 Study evaluating Itolizumab in Patients with moderate to severe Ulcerative Colitis
